SAI LIFE SCIENCES
Over the past two decades, Sai Life Sciences has served a diverse set of NCE development programmes, consistently delivering value based on its quality and responsiveness. It has a 100% successful track record of regulatory inspections across its R&D and manufacturing facilities. Today, it works with 7 of the top 10 large pharma companies, in addition to several small and mid-sized pharma & biotech companies and has over 2000 employees across its facilities in India, UK and USA.
Marking the completion of 20 years since inception in 2019, the company announced Sai Nxt, an organisation-wide initiative aimed at transforming itself into a new generation CDMO. Guided by the insights and feedback from its customers, it committed to investing over US$150M between 2019 and 2023 to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific & technological capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus.
As part of Sai Nxt, the company has added 172 KL API & Intermediate manufacturing capacity, opened a discovery biology Lab in Cambridge, Massachusetts, USA, a centre of excellence in process R&D in Manchester, UK and an 83,000 sq. ft. integrated research & technology facility in Hyderabad with technology platforms including flow chemistry, biocatalysis and crystallization. It became the first India-headquartered company to join Pharmaceutical Supply Chain Initiative (PSCI). The company is now in the process of adding high potent capability in R&D and manufacturing, a new clean room block and 200KL additional manufacturing capacity.
Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.
16 November 2020
BOOK YOUR PLACE NOW